These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 37606566)
1. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment. Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J Front Immunol; 2021; 12():669750. PubMed ID: 34054840 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer. Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X Front Immunol; 2022; 13():976107. PubMed ID: 36091006 [TBL] [Abstract][Full Text] [Related]
4. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation. Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044 [TBL] [Abstract][Full Text] [Related]
5. Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer. Xu Z; Chen Q; Shu L; Zhang C; Liu W; Wang P Front Oncol; 2022; 12():970367. PubMed ID: 36003776 [TBL] [Abstract][Full Text] [Related]
6. M6A RNA Methylation Regulator HNRNPC Contributes to Tumorigenesis and Predicts Prognosis in Glioblastoma Multiforme. Wang LC; Chen SH; Shen XL; Li DC; Liu HY; Ji YL; Li M; Yu K; Yang H; Chen JJ; Qin CZ; Luo MM; Lin QX; Lv QL Front Oncol; 2020; 10():536875. PubMed ID: 33134160 [TBL] [Abstract][Full Text] [Related]
7. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment. Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer. Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014 [TBL] [Abstract][Full Text] [Related]
9. m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer. Zhao H; Xu Y; Xie Y; Zhang L; Gao M; Li S; Wang F Front Cell Dev Biol; 2021; 9():650023. PubMed ID: 33748145 [TBL] [Abstract][Full Text] [Related]
10. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer. Liu X; Ma C; Liu H; Sun Z; Luo J J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010 [TBL] [Abstract][Full Text] [Related]
11. The potential role of RNA N6-methyladenosine in primary Sjögren's syndrome. Xiao Q; Wu X; Deng C; Zhao L; Peng L; Zhou J; Zhang W; Zhao Y; Fei Y Front Med (Lausanne); 2022; 9():959388. PubMed ID: 36465909 [TBL] [Abstract][Full Text] [Related]
12. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer. Xu LC; Pan JX; Pan HD Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956 [TBL] [Abstract][Full Text] [Related]
13. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma. Zhang T; Sheng P; Jiang Y J Cancer Res Clin Oncol; 2023 Jul; 149(7):2805-2822. PubMed ID: 35780396 [TBL] [Abstract][Full Text] [Related]
14. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma. Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X Front Genet; 2022; 13():872186. PubMed ID: 35937991 [No Abstract] [Full Text] [Related]
15. Prognostic and therapeutic implication of m6A methylation in Crohn disease. He Y; Hu Y; Yuan M; Xu W; Du Y; Liu J Medicine (Baltimore); 2022 Dec; 101(51):e32399. PubMed ID: 36595818 [TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers. Li R; Yin YH; Ji XL; Liu X; Li JP; Qu YQ Front Mol Biosci; 2021; 8():644620. PubMed ID: 34150845 [TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy. Wang Y; Sun N; He R; Wang Z; Jin J; Gao T; Qu J Clin Exp Med; 2024 May; 24(1):92. PubMed ID: 38693353 [TBL] [Abstract][Full Text] [Related]
18. Characterizing m6A modification factors and their interactions in colorectal cancer: implications for tumor subtypes and clinical outcomes. Sun W; Su Y; Zhang Z Discov Oncol; 2024 Sep; 15(1):457. PubMed ID: 39292326 [TBL] [Abstract][Full Text] [Related]
19. The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma. Liu T; Li C; Jin L; Li C; Wang L Med Sci Monit; 2019 Dec; 25():9435-9445. PubMed ID: 31823961 [TBL] [Abstract][Full Text] [Related]
20. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer. Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]